logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Alumis Inc. raised $259M in a upsized funding round to support its clinical-stage biopharmaceutical development.

Mar 07, 2024•almost 2 years ago

Amount Raised

$259 Million

Round Type

series c

San FranciscoBiotechnologyHealth Care

Investors

Venture Capital Investors

Description

South San Francisco-based clinical-stage biopharmaceutical company Alumis Inc. closed its upsized Series C funding round after securing $259 million from venture capital investors.

Company Information

Company

Alumis

Location

San Francisco, California, United States

About

A California-based biotech company specializing in developing oral therapies for immune dysfunction and autoimmune indications, with a focus on TYK2 inhibition.

Related People

29 contacts

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech